Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease

Creative Commons License

Yuzbasioglu B., Ustaoğlu Dede M., Yuzbasioglu S., Akbulut U. E., Ozdil K.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.12, pp.1025-1029, 2019 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 12
  • Publication Date: 2019
  • Doi Number: 10.5152/tjg.2019.19346
  • Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1025-1029
  • Keywords: Crohn's disease, thrombophilia, ulcerative colitis, ACTIVATABLE FIBRINOLYSIS INHIBITOR, FACTOR PATHWAY INHIBITOR, TISSUE FACTOR, THROMBOSIS, RISK, COAGULATION, STATE, WOMEN
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13) in patients with IBD and to assess their possible role in the etiopathogenesis of the disease.